AIMC Topic: Poly(ADP-ribose) Polymerase Inhibitors

Clear Filters Showing 11 to 13 of 13 articles

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.

Clinical pharmacology in drug development Jan 26, 2015
PURPOSE: Rucaparib is a potent Poly (ADP-ribose) Polymerase (PARP) inhibitor currently under clinical development. The objectives of this analysis were to establish population PK and PK/PD models for rucaparib, and to evaluate the predictability of P...
Humans Biomarkers Computer Simulation Neoplasms Infusions, Intravenous Models, Biological Lymphocytes Indoles Drug Administration Schedule Poly(ADP-ribose) Polymerases Poly(ADP-ribose) Polymerase Inhibitors
View on PubMed DOI

HRProfiler Detects Homologous Recombination Deficiency in Breast and Ovarian Cancers Using Whole-Genome and Whole-Exome Sequencing Data.

Cancer research Jul 2, 2025
UNLABELLED: Breast and ovarian cancers harboring homologous recombination deficiency (HRD) are sensitive to PARP inhibitors and platinum chemotherapy. Conventionally, detecting HRD involves screening for defects in BRCA1, BRCA2, and other relevant ge...
Humans Machine Learning Retrospective Studies Female Breast Neoplasms Ovarian Neoplasms Mutation Whole Genome Sequencing Exome Sequencing Poly(ADP-ribose) Polymerase Inhibitors Homologous Recombination
View on PubMed DOI

ChemMORT: an automatic ADMET optimization platform using deep learning and multi-objective particle swarm optimization.

Briefings in bioinformatics Jan 22, 2024
Drug discovery and development constitute a laborious and costly undertaking. The success of a drug hinges not only good efficacy but also acceptable absorption, distribution, metabolism, elimination, and toxicity (ADMET) properties. Overall, up to 5...
Humans Drug Discovery Deep Learning Drug Development Poly(ADP-ribose) Polymerase Inhibitors
View on PubMed DOI
Popular Topics
Recent Journals